

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/46, 31/44	A1	(11) International Publication Number: WO 97/25030 (43) International Publication Date: 17 July 1997 (17.07.97)
<p>(21) International Application Number: PCT/SE96/01738</p> <p>(22) International Filing Date: 20 December 1996 (20.12.96)</p> <p>(30) Priority Data: 9600073-2 8 January 1996 (08.01.96) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): LUNDBERG, Per, Johan [SE/SE]; Torsgatan 6, S-431 38 Mölndal (SE).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: MULTIPLE UNIT EFFERVESCENT DOSAGE FORMS COMPRISING PROTONPUMP INHIBITOR</p> <p>(57) Abstract</p> <p>A new tableted multiple unit effervescent dosage form containing an acid susceptible proton pump inhibitor in the form of the racemate, an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, and effervescent tablet constituents. The proton pump inhibitor is preferably omeprazole or an alkaline salt thereof, or S-omeprazole or an alkaline salt thereof. Further the invention refers to a method for the manufacture of such a formulation, and the use of such a formulation in medicine.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Multiple unit effervescent dosage forms comprising
protonpump inhibitor.

Field of the invention.

5 The present invention is related to new pharmaceutical preparations in the form of a
tableted multiple unit effervescent dosage form comprising an active substance in the form
of an acid susceptible proton pump inhibitor, i.e. acid labile H^+K^+ ATPase inhibitors. The
novel tableted dosage form is intended for oral use. Furthermore, the present invention
refers to a method for the manufacture of such preparations and, to the use of such
10 preparations in medicine.

Background of the invention

15 Acid labile H^+K^+ ATPase inhibitors also named as proton pump inhibitors are for instance
compounds known under the generic names omeprazole, lansoprazole, pantoprazole,
pariprazole, leminoprazole and others.

These active substances are useful for inhibiting gastric acid secretion in mammals and
20 especially in man. In a more general sense, they may be used for prevention and treatment
of gastric-acid related diseases in mammals and especially in man, including e.g. reflux
oesophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may
be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect
is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in
25 patients with symptomatic gastro oesophageal reflux disease, and in patients with
gastrinomas. They may also be used in patients in intensive care situations, in patients with
acute upper gastrointestinal bleeding, pre-and postoperatively to prevent aspiration of
gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the
treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases
30 related to these.

The active compounds are, however, susceptible to degradation/transformation in acidic reacting and neutral media. The degradation is catalyzed by acidic reacting compounds. The active compounds are stabilized with alkaline reacting compounds. Thus, the active
5 substance being a proton pump inhibitor is best protected by an enteric coating layer. There are different enteric coating layered preparations of omeprazole as well as other proton pump inhibitors described in the prior art, see for example US-A 4,786,505 (AB Hässle).

There has been a demand for a formulation with a rapid dissolution and a quick onset of
10 action, furthermore a formulation which is pleasant to take for the patient and also which is suitable for patients with swallowing difficulties (dysphagia). There are a number of dosage forms that hold a good deal of promise in administering proton pump inhibitors. However, it has been difficult to find a vehicle which can satisfy all of many and some times conflicting needs and desires for such a dosage form.

15

One possible vehicle for administration of these active agents is effervescent tablets.

Effervescence provides generally some measure of taste-masking. Prior to being taken by the patient, an effervescent composition is dissolved and/or dispersed in for example an aqueous medium, such as drinking water. Dissolution and/or dispersion takes place rapidly,
20 with effervescence to give an agreeable presentation of the drug, particularly for patients who do not like tablets or find difficulty in swallowing tablets.

Effervescent compositions usually contain, in addition to the active ingredient, a source of carbon dioxide (such as an alkaline carbonate or bicarbonate) and an acid (such as for
25 instance citric acid). The use of an acid in effervescent compositions in which the active ingredient is an acid labile substance such as an acid susceptible proton pump inhibitor presents a problem due to the instability of the proton pump inhibitor in the presence of acid.

Replacement of citric acid by monosodium citrate still fails to give a satisfactory level of stability of an acid labile histamine H₂ -antagonist, whilst replacement of citric acid by disodium citrate results in insufficient effervescence and a prolonged dissolution time. EP 233853 proposes a mixture of monosodium citrate and disodium citrate as a solution to the problem. GB 2 219 940 A, proposes replacement of citric acid or the mixture of citrates
5 proposed in EP 233853 by a monoalkalimetal citrate (monosodium citrate).

Effervescent tablets containing acid-sensitive agents have been manufactured by coating the acidic particles in the acid-base couple with a coating of a base to separate the
10 pharmaceutically active substance, i.e. the acid-sensitive agent, from the acid of the effervescence, see for instance WO 94 21,239. The proposed solution results in that the active drug comes into contact with the resulting buffer when dissolving the tablet. Thus, the active drug must be stable in that buffer at the given pH. Furthermore, if the active drug has a bad taste, there will be problems to mask it. (For instance, omeprazole is such a
15 compound that has a strongly bitter taste).

Another way to make effervescent tablets containing acid-labile drugs, such as erythromycine, has been proposed as described in US 4,289,751. The active substance is incorporated in the effervescent tablet, in intimate contact with the effervescing acid-base
20 couple. The effervescent tablet is then coated with an enteric coating polymer. The aim of the preparation is that the tablet will be protected from the strongly acidic environment in the stomach by the enteric coating layer during the passage thereof. In the small intestines, the enteric coating layer is dissolved and the effervescent effect takes place in the intestines. One drawback with such a dosage form is that patients can experience problems due to the
25 carbon dioxide liberated inside the gastrointestinal channel. Another drawback is varying residence time in the stomach before the tablet can arrive to an environment where the active substance can be dissolved, absorbed and can exert its effect.

Korean pat. appl. No. 93-17902 proposes another composition comprising an enteric
30 coated tablet with an effervescent mixture layer inside the enteric coating. Also Korean pat.

appl. No. 94-3190 describes a formulation of omeprazole with an effervescent mixture inside the enteric coating.

A way to circumvent the problems associated with the composition proposed in US 4,289,751, i.e. with carbon dioxide created inside the gastrointestinal channel etc., and to avoid direct contact between the pharmaceutically active substance, i.e. the acid-labile compound, and acidic substances of the effervescence, and further to avoid direct contact of the active substance with a solution buffered to unsuitable pH, would be to use the active substance in the form of small enteric coating layered units comprising the pharmaceutically active substance. Such units are coating layered with a polymeric layer not dissolving in the solution formed when the effervescent tablet is dissolved. These small coating layered units are taste-masked as they maintain their coating layer intact during and after intake of the effervescent dispersion and during passage of the stomach. The coating layer starts to dissolve upon arrival at the appropriate place in the gastrointestinal channel, i.e. in the small intestines (duodenum). The present invention now surprisingly provides such enteric coating layered units suitable for an effervescent formulation.

Preparation of a multiple unit tableted dosage form arises specific problems when enteric coating layered pellets containing acid susceptible proton pump inhibitors as active substances are compressed into tablets. If the enteric coating layer does not withstand the compression of the pellets into a tablet the susceptible active substance will be destroyed both by the acidic solution/dispersion formed upon effervescence or by penetrating acidic gastric juice upon administration, i.e. the acid resistance of the enteric coating layer of the pellets will not be sufficient in the tablet after compression.

Summary of the invention

The Applicant has now surprisingly found that effervescent tablets according to the present invention comprising enteric coated units of an acidic susceptible proton pump inhibitor can be manufactured by compressing said units into tablets without significantly affecting the

properties of the enteric coating. As explained above, if the enteric coating is damaged during compression of the enteric coated units the acid resistance of said enteric coating in the manufactured tablets will not be sufficient and the manufactured tablets will not fulfil standard requirements on enteric coated articles, such as those defined in the United States Pharmacopeia USP. Furthermore, the active substance may be destroyed by the acidic solution/dispersion obtained by the effervescence, if such requirements not are fulfilled.

One object of the present invention is to provide a tableted multiple unit effervescent dosage form comprising an acid susceptible proton pump inhibitor, or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, in which the active substance is in the form of enteric coating layered units compressed together with effervescent tablet excipients into such an effervescent tablet. The enteric coating layer(s) covering the individual units of active substance has properties such that the compression of the units into a tablet does not significantly affect the acid resistance of the enteric coated units. The active substance is prevented from degradation and dissolution in acidic media and the dosage form has a good stability during long-term storage. The enteric coating covering the individual units disintegrates/dissolves rapidly in near neutral or alkaline media.

The tableted multiple unit effervescent dosage form is especially suitable for patients with swallowing disorders and in pediatrics.

Detailed description of the invention.

The novel tableted multiple unit effervescent dosage form comprising an active substance in the form of an acid susceptible proton pump inhibitor, or an alkaline salt thereof or one of its single enantiomers, or an alkaline salt thereof is characterized in the following way.

An effervescent tablet is compressed from a mixture of enteric coated layered pellets comprising the active substance and effervescent tablet constituents, and optionally other tablet excipients. Dissolution of the tablet in water gives such a pH value that the enteric

coating layer of the pellets will not dissolve, i.e. a pH value normally less than 5.5, but depending on the specific enteric coating material used. Furthermore, the formulation is characterized in that the tablet *per se* is rapidly dissolving, and that it may contain taste improving agents, colourants, technical additives such as lubricating agents, disintegrants and wetting agents, and other tablet excipients.


The enteric coating layered units containing active substance and optionally alkaline reacting substances, are mixed with effervescent tablet constituents and optionally other excipients. The mixture is compressed into a tableted multiple unit effervescent dosage form. With the expression "units" is meant small beads, particles, granules or pellets, in the following referred to as pellets. All of or parts of the effervescent constituents may be granulated before compression or directly compressed together with the enteric coating layered units.

The compaction process (compression) for formulating the tableted multiple unit effervescent dosage form must not significantly affect the acid resistance of the enteric coating layered pellets. In other words the mechanical properties, such as the flexibility and hardness as well as the thickness, of the enteric coating layer(s) must secure that the requirements on enteric coated articles in the United States Pharmacopeia USP are accomplished and the acid resistance does not decrease more than 10% during the compression of pellets into tablets.

The acid resistance is defined as the amount of active substance in tablets or pellets after being exposed to simulated gastric fluid, USP, or to 0.1 M HCl(aq) relative to that of unexposed tablets or pellets, respectively. The test is accomplished in the following way. Tablets or pellets are exposed to simulated gastric fluid at a temperature of 37°C. The tablets disintegrate and release the enteric coated pellets to the medium. After two hours the enteric coated pellets are removed and analyzed for active substance content using High Performance Liquid Chromatography (HPLC).


Active substances

The proton pump inhibitors are for example compounds of the general formula I




wherein


Het₁ is




or




Het₂ is




or




or



X =



or



wherein

N in the benzimidazole moiety means that one of the carbon atoms substituted by R₆-R₉ optionally may be exchanged for a nitrogen atom without any substituents;

R₁, R₂ and R₃ are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

5

R₄ and R₅ are the same or different and selected from hydrogen, alkyl and aralkyl;

R'₆ is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R₆-R₉ are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-


10 alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R₆-R₉ form ring structures which may be further substituted;

R₁₀ is hydrogen or forms an alkylene chain together with R₃ and




15 R₁₁ and R₁₂ are the same or different and selected from hydrogen, halogen or alkyl and alkyl groups, alkoxy groups and moieties thereof may be branched and straight C₁-C₉-chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

Examples of proton pump inhibitors according to formula I are

20




Omeprazole




Lansoprazole


5



Pantoprazole








Pariprazole



Leminoprazole

5





5

The proton pump inhibitors used in the dosage forms of the invention may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg^{2+} , Ca^{2+} , Na^+ , K^+ or Li^+ salts, preferably the Mg^{2+} salts. Further where applicable, the compounds listed

10 above may be used in racemic form or in the form of a substantially pure enantiomer thereof, or alkaline salts of the single enantiomers.

Suitable proton pump inhibitors are for example disclosed in EP-A1-0005129, EP-A1-174 726, EP-A1-166 287, GB 2 163 747 and WO90/06925, WO91/19711,

15 WO91/19712, and further especially suitable compounds are described in WO95/01977 and WO94/27988.

The effervescent tablet constituents used in the tableted dosage form according to the present invention must not interfere in a disadvantageously manner with the active substance in the prepared tablet. Thus, the buffering components in the effervescent system should, 5 dissolved in water, result in a solution with a pH value that is below the pKa of the enteric coating polymer used on the individually enteric coating layered units comprising the acid susceptible proton pump inhibitor. In most cases the pH value of the obtained solution/dispersion formed upon effervescence should be below 5.5, but depends on the specific enteric coating polymer used. The pH is important to ensure that the enteric coating 10 layer of the units remain intact during the administration to protect the acid susceptible proton pump inhibitor during passage of the stomach, and later disintegrate/dissolve in the small intestine where dissolution of the active substance is desired.

The buffering components of the effervescent constituents can generally be divided in two 15 categories; a carbon dioxide source and an acidic component. The latter reacts with the carbon dioxide source resulting in the development of carbon dioxide gas. The effervescent constituents may also include other tableting excipients such as for instance binding agents, diluents, lubricants, disintegrating agents, surfactants, taste improving agents, colorants or the like.

20

As carbon dioxide source can be used for instance alkali metal carbonates or bicarbonates, alkaline earth metal carbonates or bicarbonates, or other inorganic salts containing carbonate or bicarbonate ions.

25 Acidic components suitable to incorporate in an effervescent tablet are preferably solid acidic compounds and include for instance monosodium dihydrogen phosphate, or tartaric acid, citric acid and other weak organic acids.

Further components used in the preparation according to the present invention are described 30 more in detail below.

Core material - containing an acid susceptible proton pump inhibitor.

The core material for the individually enteric coated pellets can be constituted according to different principles. Inert seeds layered with active substance, optionally mixed with alkaline
5 reacting compounds, can be used as the core material for the further processing.

The seeds which are to be layered with the acid susceptible proton pump inhibitor can be water insoluble seeds comprising different oxides, celluloses, organic polymers and other materials, alone or in mixtures or water-soluble seeds comprising different inorganic salts,
10 sugars, non-pareils and other materials, alone or in mixtures. Further, the seeds may comprise the proton pump inhibitor in the form of crystals, agglomerates, compacts etc. The size of the seeds is not essential for the present invention but may vary between approximately 0.1 and 2 mm. The seeds layered with the proton pump inhibitor are produced either by powder or solution/suspension layering using for instance granulation or
15 spray coating layering equipment.

Before the seeds are layered the active substance may be mixed with further components. Such components can be binders, surfactants, fillers, disintegrating agents, alkaline reacting additives or other pharmaceutically acceptable ingredients, alone or in mixtures. The binders
20 are for example polymers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose and carboxymethylcellulose sodium, polyvinyl pyrrolidone, sugars, starches or other pharmaceutically acceptable substances with cohesive properties. Suitable surfactants are found in the groups of pharmaceutically acceptable non-ionic or ionic surfactants such as for instance sodium lauryl sulfate.

25

Alternatively, the core material can be prepared as substantially homogeneous cores containing omeprazole or one of its single enantiomers or an alkaline salt of omeprazole or one of its single enantiomers mixed with suitable constituents, optionally mixed with alkaline reacting compounds. Said core materials may be produced by
30 extrusion/spheronization, balling or compression utilizing different process equipments.

The size of the formulated homogeneous core material is approximately between 0.1 and 4 mm and preferably between 0.1 and 2 mm. The manufactured homogeneous core materials can be further layered with additional ingredients comprising active substance and/or used for further processing.

5

The active substance is mixed with pharmaceutical constituents to obtain preferred handling and processing properties and a suitable concentration of active substance in the final mixture. Pharmaceutical constituents such as fillers, binders, lubricants, disintegrating agents, surfactants and other pharmaceutically acceptable additives, can be used.

10

The active substance may also be mixed with an alkaline reacting pharmaceutically acceptable substance (or substances). Such substances can be chosen among, but are not restricted to, substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate coprecipitate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances.

20

Alternatively, the aforementioned core material can be prepared by using spray drying or spray congealing technique.

25

The active substance is in the form of an acid labile H^+K^+ ATPase inhibitor according to formula I or an alkaline salt thereof or one of its single enantiomers. These compounds have an asymmetric centre in the sulfur atom, i.e. exists as two optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two enantiomers are suitable for the pharmaceutical formulation according to the present invention.

30

Enteric coating layer(s) - for enteric coating layering of the core material of a proton pump inhibitor.

- 5 Before applying enteric coating layer(s) onto the core material in the form of individual pellets, said pellets may optionally be covered with one or more separating layers comprising pharmaceutical excipients optionally including pH-buffering, alkaline compounds. This/these separating layer(s) separate(s) the core material from the outer layer(s) being enteric coating layer(s). The separating layer(s) protecting the core material
10 of a proton pump inhibitor should be water soluble or rapidly disintegrating in water.

The separating layer(s) can be applied on to the core material by coating or layering procedures in suitable equipments such as coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating process. As an alternative
15 the separating layer(s) can be applied to the core material by using coating technique. The materials for separating layers are chosen among the pharmaceutically acceptable compounds such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methyl cellulose, carboxymethylcellulose sodium and others, used alone or in
20 mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the separating layer(s).

When the optional separating layer(s) is applied to the core material it may constitute a
25 variable thickness. The maximum thickness of the optional separating layer(s) is normally only limited by processing conditions. The separating layer(s) may serve as a diffusion barrier and may act as a pH-buffering zone. The pH-buffering properties of the separating layer(s) can be further strengthened by introducing into the layer(s) substances chosen from a group of compounds usually used in antacid formulations such as, for instance,
30 magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance

$\text{Al}_2\text{O}_3.6\text{MgO.CO}_2.12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3.4\text{H}_2\text{O})$, $\text{MgO.Al}_2\text{O}_3.2\text{SiO}_2.n\text{H}_2\text{O}$, aluminium hydroxide/sodium bicarbonate coprecipitate or similar compounds; or other pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, weak, inorganic or organic acids; or suitable organic bases, including basic amino acids and salts thereof. Talc or other compounds may be added to increase the thickness of the layer(s) and thereby strengthen the diffusion barrier. The optionally applied separating layer(s) is not essential for the invention. However the separating layer(s) may improve physical and chemical properties of the novel multiple unit tableted dosage form.

10

Alternatively, the separating layer may be formed *in situ* by a reaction between an enteric coating polymer layer applied on the core material and an alkaline reacting compound in the core material. Thus, the separating layer formed comprises a water soluble salt formed between the enteric coating layer polymer(s) and an alkaline reacting compound which is in the position to form a salt.

15

One or more enteric coating layers are applied onto the core material or onto the core material covered with separating layer(s) by using a suitable coating technique. The enteric coating layer material may be dispersed or dissolved in either water or in suitable organic solvents. As enteric coating layer polymers one or more, separately or in combination, of the following can be used; e.g. solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac or other suitable enteric coating layer polymer(s).

25

The enteric coating layers contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness of the enteric coating layers. Such plasticizers are for instance, but not restricted to, cetanol, triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, polyethylene glycol, polysorbates or other plasticizers.

30

The amount of plasticizer is optimized for each enteric coating layer formula, in relation to selected enteric coating layer polymer(s), selected plasticizer(s) and the applied amount of said polymer(s), in such a way that the mechanical properties, i.e. flexibility and hardness of the enteric coating layer(s), for instance exemplified as Vickers hardness are adjusted so that the acid resistance of the pellets covered with enteric coating layer(s) does not decrease significantly during the compression of pellets into tablets. The amount of plasticizer is usually in the range of 1-50 % by weight of the enteric coating layer polymer(s), preferably 10 - 50 % and more preferably 15 - 50 %. Additives such as dispersants, colorants, pigments, polymers e.g. poly(ethylacrylat, methylmethacrylat), anti-tacking and anti-foaming agents may also be included into the enteric coating layer(s). Other compounds may be added to increase film thickness and to decrease diffusion of acidic gastric juices into the acid susceptible material.

To protect an acid susceptible proton pump inhibitor and to obtain an acceptable acid resistance of the multiple unit tableted dosage form, according to the invention the enteric coating layer(s) constitutes a thickness of approximately at least 10 μm , preferably more than 20 μm . The maximum thickness of the applied enteric coating layer(s) is normally limited by processing conditions, and the desired dissolution profile.

Over-coating layer

Pellets covered with enteric coating layer(s) may further be covered with one or more over-coating layer(s). This over-coating layer(s) should be water soluble or rapidly disintegrating in water. The over-coating layer(s) can be applied to the core material by coating or layering procedures in suitable equipments such as coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating process. The materials for over-coating layers are chosen among the pharmaceutically acceptable compounds such as, for instance sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methyl cellulose, carboxymethylcellulose sodium and others, used alone or in

mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the over-coating layer(s). Said over-coat may further prevent potential agglomeration of coated pellets, protect the enteric coating towards
5 cracking during the compaction process and enhance compressability during tableting. The maximum thickness of the applied over-coating layer(s) is normally limited by processing conditions, and the desired dissolution profile. The above described over-coating layer may also be used as a tablet coating layer to obtain tablets of good appearance.

10 Effervescent preparation

The effervescent constituents can be dry mixed, wet granulated, compacted, melt granulated or prepared according to any known granulation technique. When wet granulated the acidic component may be granulated separately or in combination with the carbon dioxide source.
15 If granulated in combination, it is advantageous to use a granulation liquid that contains as little water as possible, e.g. ethanol 99 %.

Effervescent tablets

20 The enteric coating layered pellets comprising an acid susceptible proton pump inhibitor are mixed with effervescent constituents and optionally with tablet excipients such as fillers, binders, disintegrants, lubricants and other pharmaceutical acceptable additives and compressed into a multiple unit tableted dosage form according to the present invention. The proton pump inhibitor as well as the effervescent constituents are defined above.

25

By choosing small enteric coated pellets in the formulation according to the present invention, the fraction of pellets in each tablet can be held high and the pellets evenly distributed within the tablet and easily dispersible upon effervescence.

30 Thus, the formulation according to the invention consists of core material containing an active substance, optionally mixed with alkaline reacting compound(s), and tablet

excipients. The addition of an alkaline reacting material may not be necessary, but such a substance may further enhance the stability of the active substance. The core material is optionally coated with one or more separating layer(s) optionally containing pH-buffering substance(s). The pellets, optionally covered with a separating layer(s), are then covered
5 with one or more enteric coating(s) rendering the pellets being insoluble in acidic media, but disintegrating/ dissolving in near neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine where dissolution is desired. The enteric coating layered pellets may further be covered with an over-coat before formulated together with the effervescent constituents into the tableted multiple unit effervescent dosage form as
10 mentioned above.

Process

The process for the manufacture of the dosage form represents a further aspect of the
15 invention. The pharmaceutical processes can preferably be completely water-based and different ways to practice the invention are described in the accompanying examples below.

Use of preparation

20 The preparation according to the invention is especially advantageous in reducing gastric acid secretion. It is administered one to several times a day, preferable once or twice daily. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and disease. In general the daily dose will be in the range of 1-1000 mg of active substance. Preferred
25 dosages are 10-100 mg of the proton pump inhibitor.

The present invention is described in more detail by the following non-limiting example.

Example 1.

30 Effervescent tablets containing 20 mg omeprazole.

Manufacturing of pellets containing magnesium omeprazole.

Core material

5	Magnesium omeprazole	12.00 kg
	Non-pareil cores	12.00 kg
	Hydroxypropyl methylcellulose	1.8 kg
	Water purified	35.4 kg

10 Separating layer

	Core material (acc. to above)	23.50 kg
	Hydroxypropyl cellulose	2.35 kg
	Talc	4.03 kg
	Magnesium Stearate	0.34 kg
15	Water purified	48.00 kg

Enteric coating layer

	Pellets with a sep layer (acc. to above)	29.00 kg
	Methacrylic acid copolymer (30% suspension)	38.70 kg
20	Triethyl citrate	3.48 kg
	Mono- and diglycerides (NF)	0.58 kg
	Polysorbate 80	0.06 kg
	Water purified	22.68 kg

25 Over-coating layer

	Enteric coated pellets (acc. to above)	44.7 kg
	Hydroxypropyl methylcellulose	0.58 kg
	Mg-Stearate	0.02 kg
	Water purified	11.6 kg

Suspension layering was performed in a fluid bed apparatus. Magnesium omeprazole was sprayed onto inert suger seeds (non-pareil cores) from a water suspension containing the dissolved binder.

- 5 The prepared core material was coating layered with a separating layer in a fluid bed apparatus with a hydroxypropyl cellulose solution containing talc and magnesium stearate. The enteric coating layer consisting of methacrylic acid copolymer, mono- and diglycerides, triethylcitrate and polysorbate was sprayed onto the pellets (layered with a separating layer) in a fluid bed apparatus. In the same type of apparatus the enteric coating layered pellets
10 were coated with hydroxypropyl methylcellulose/Mg-stearate suspension. The pellets covered by an over-coating layer were classified by sieving.

The obtained enteric coating layered pellets were mixed with prepared granules and other components as described below and thereafter compressed to effervescent tablets.

15

Granulation (1 000 tablets);

	Citric acid anhydrous	605 g
	Mannitol dried	200 g
	Riboflavine	0.1 g
20	Polyvinylpyrrolidone K-25 (PVP K-25)	6.0 g
	EtOH 99%(w/v)	90 g

- The PVP K-25 was dissolved in the ethanol to give the granulating solution. In this solution the riboflavine was dispersed. The citric acid and mannitol were mixed and the liquid was
25 added and the mass further mixed. Then the mass was put on a tray and dried in a drying oven for approx. 2 hrs at 55 degrees Celsius. The granulate was milled to pass sieve 1.0 mm.

A pre-mix consisting of the following was prepared by dry mixing in a turbula mixer;

30

	Sodium carbonate anhydrous	36 g
	Sodium dodecyl sulphate	1 g
	Sodium stearyl fumarate	14 g
	Essence orange	2.0 g
5	Saccharine Sodium	2.0 g
	Polyvinyl pyrrolidone cross-linked	70 g
	Enteric coated pellets from above	95.7 g

Final mixing was performed in a Kenwood mixer where the following ingredients were dry
10 mixed:

	Granulate from above	811.1 g
	Premix from above	220.7 g
	Sodium bicarbonate	453 g

15

The final mixing time was 4 minutes.

Compression to tablets was done on a tableting machine equipped with punches giving 20
mm diameter flat tablets with bevelled edges.

20

Tablet weight was 1485 mg. The compressed tablets had an average height of 3.6 mm
(n=10). The effervescence time of the tablets was measured by placing the tablet in a
basket of metal wiring and then immersing the basket in 300 ml of water at 20 degrees
Celsius. The effervescence time was considered finished when there was no material left in
25 the immersed basket. For this tablet composition the time was 30 seconds.

One tablet was placed in 100 ml purified water. The pH of the obtained dispersion was 4.8.
Another tablet was exposed for 0.1 M HCl during 2 hours. The liberated enteric coated
units were transferred to phosphate buffer solution of pH 6.8. After 30 min 91 % of the
30 omeprazole dose was found in the solution.

Example 2

Preparation of enteric coating layered pellets containing lansoprazole.

5 Core material

Non-pareil cores	400	g
Lansoprazole	400	g
Hydroxypropyl methylcellulose	80	g
Sodium laurylsulphate	3	g
10 Water purified	1360	g

Separating layer

Core material (acc. to above)	100	g
Hydroxypropyl methylcellulose	9	g
15 Polyethyleneglycol 6000	1	g
Talc	18	g
Ethanol 95%	250	g
Water purified	250	g

20 Enteric coating layer

Sub-coated pellets (acc. to above)	100	g
Hydroxypropyl methylcellulose phtalate	40	g
Acetyltributyl citrate	8	g
Cetanol	2	g
25 Ethanol 95%	162	g
Acetone	378	g

Suspension layering was performed in a Wurster equipped fluid bed apparatus.

Lansoprazole was sprayed onto inert non-pareil cores from a water suspension containing lansoprazole, the dissolved binder and the wetting agent.

- 5 The prepared core material was coating layered with a separating layer in the same equipment by spraying a suspension of talc in a HPMC/PEG- solution. PEG was added to act as a plasticizer for the HPMC.

- 10 Enteric coating layer was applied in the same equipment by spraying the enteric coating polymer solution (including additives according to above) onto the pellets (layered with a separating layer). The obtained enteric coating layered pellets were mixed with prepared granules and other component as described in example 1, and compressed into effervescent tablets.

15 Example 3

Effervescent tablets 20 mg containing 20 mg omeprazole

Manufacturing of pellets.

20 Core material

Suspension for layering

Magnesium omeprazole	5.0 kg
Hydroxypropyl methylcellulose	0.8 kg
Water purified	14.3 kg

25

Seeds for layering

Non-pareil cores	10.0 kg
------------------	---------

- 30 The active substance was suspended in a solution prepared of the hydroxypropyl methylcellulose in the water, and thereafter homogenized in a ball mill.

The suspension was sprayed onto the seeds in a Wurster equipped fluidized bed apparatus.

Separating layer

	Core material (acc. to above)	14.6 kg
5	Hydroxypropyl cellulose	1.5 kg
	Talc	2.5 kg
	Magnesium Stearate	0.2 kg
	Water purified	29.2 kg

- 10 The talc and magnesium stearate were suspended in a solution prepared by dissolving the hydroxypropyl cellulose in the water. The suspension was sprayed onto the core material in the same equipment as above.

Enteric coating layer

15	Prepared pellets (acc. to above)	250 g
	Methacrylic acid copolymer (30% suspension)	458 g
	Triethyl citrate	41 g
	Titanium dioxide	19 g
20	Mono- and diglycerides (NF)	7 g
	Polysorbate 80	0.7 g
	Water purified	329 g

- 25 The pH of the methacrylic acid copolymer coating suspension was first adjusted to 4.0 by adding 14 ml of 0.5 M sodium hydroxide solution. Thereafter all of the triethylcitrate was added. (= Suspension A.)

- 30 The polysorbate 80 was mixed with 120 g of water, whereafter the mono- and diglycerides was added and this mixture was heated to above 70°C for 10 minutes and the cooled during agitation to room temperature. (= Emulsion B.)

The titanium dioxide was suspended in 120 g of water. The pH of the suspension was 4.4.
(= Suspension C.)

- 5 The emulsion B, the suspension C and 89 g of water were added to suspension A. The pH of the mixture was checked and found to be 4.2.

(At pH below 4.5 this enteric coating suspension showed no signs of precipitation.)

- 10 The suspension (during agitation with a magnetic stirrer) was sprayed onto the core material in a Wurster equipped fluidized bed apparatus.

The obtained enteric coated pellets were mixed with powders and effervescent granules and thereafter compressed to effervescent tablets.

15

Effervescent granules;

	Citric acid anhydrous	11.4 kg
	Sodium bicarbonate	8.4 kg
20	Polyvinylpyrrolidone K-25 (PVP K-25)	0.3 kg
	EtOH 99%(w/v)	0.8 kg
	water purified	0.3 kg

- 25 The PVP K-25 was dissolved in the ethanol + water to give the granulating solution. This solution was used to granulate the citric acid sodium bicarbonate mixture. The wet mass was dried at 55°C, and after cooling to room temperature the granulate was milled to pass sieve 1.1 mm.

A pre-mix (for 400 tablets) was prepared by dry mixing in a Kenwood mixer the following;

30

27

Sodium carbonate anhydrous	38	g
Sorbitol	160	g
Antifoam M	5.8	g

- 5 The premix was passed through a 0.5 mm sieve.

Final mixing (for 400 tablets) was performed in the same Kenwood mixer where the following ingredients were dry mixed:

10 Effervescent granules from above	909	g
Premix from above	204	g
Sodium steryl fumarate (passing sieve 0.5 mm)	7	g
Enteric coated pellets from above	70	g

- 15 Compression to tablets was done on a tableting machine equipped with punches giving 25 mm diameter flat tablets.

Tablet weight was 2970 mg. The compressed tablets had an average height of 4.3 mm (n=4) and an average hardness of 77 N (n= 10). The effervescence time of the tablets was
20 measured by putting the tablet in a basket of metal wiring and then immersing the basket in 150 ml of water (20 degrees Celsius). The effervescence time was considered finished when there was no material left in the immersed basket. For this tablet composition the time was 55 seconds.

- 25 The pH of the obtained dispersion testing in the tablet in 150 ml purified water was 5.0.

Gastric juice resistance (determined as % of the dose omeprazole remaining after exposure for 0.1 M HCl during 2 hours) was 91%.

Example 4

Effervescent tablets containing 40 mg omeprazole.

Manufacturing of pellets.

5

Core materialSuspension for layering

Magnesium omeprazole 5.5 kg

Hydroxypropyl methylcellulose 0.8 kg

10 Water purified 15.7 kg

Seeds for layering

Non-pareil cores 11.0 kg

15 The active substance was suspended in a solution prepared of the hydroxypropyl methylcellulose in the water, and thereafter homogenized in a ball mill.

The suspension was sprayed onto the seeds in a Wurster equipped fluidized bed apparatus.

Separating layer

20 Core material (acc. to above) 16.0 kg

Hydroxypropyl cellulose 1.6 kg

Talc 2.7 kg

Magnesium Stearate 0.2 kg

Water purified 32 kg

25

The talc and magnesium stearate were suspended in a solution prepared by dissolving the hydroxypropyl cellulose in the water. The suspension was sprayed onto the core material in the same equipment as above.

Enteric coating layer

	Prepared Pellets (acc. to above)	20 kg
	Methacrylic acid copolymer (30% dispersion)	33 kg
	Triethyl citrate	3 kg
5	Mono- and diglycerides (NF)	0.5 kg
	Polysorbate 80	0.05kg
	Water purified	20.5 kg

The methacrylic acid copolymer dispersion was mixed with 1.0 kg of water and the
10 triethylcitrate during agitation. (= Dispersion A.)

The polysorbate 80 was mixed with 19.5 kg of water, whereafter the mono- and
diglycerides was added and this mixture was heated to above 70°C for 10 minutes and the
cooled during agitation to room temperature. (= Emulsion B.)

15

The emulsion B was added to suspension A and mixed to homogeneity.

The suspension (during agitation with a magnetic stirrer) was sprayed onto the core material
in a Wurster equipped fluidized bed apparatus.

20

Directly after the enteric coating dispersion was applied, the pellets in the fluidized bed were
sprayed with a hydroxypropyl methylcellulose solution containing magnesium stearate
dispersed therein to accomplish an overcoating layer.

The composition of the dispersion was;

25

	Water purified	8.0 kg
	Hydroxypropyl methylcellulose	0.4 kg
	Magnesium stearate	0.01 kg

The obtained (overcoated) enteric coated pellets were mixed with powders and effervescent granules and thereafter compressed to effervescent tablets.

5 Effervescent granules;

Citric acid anhydrous	11.4	kg
Sodium bicarbonate	8.4	kg
Polyvinylpyrrolidone K-25 (PVP K-25)	0.3	kg
EtOH 99%(w/v)	0.8	kg
10 water purified	0.3	kg

The PVP K-25 was dissolved in the ethanol + water to give the granulating solution. This solution was used to granulate the citric acid sodium bicarbonate mixture. The wet mass was dried at 55°C and after cooling to room temperature the granulate was milled to pass
15 sieve 1.1 mm.

A pre-mix (for 400 tablets) was prepared by dry mixing in a Kenwood mixer the following;

Sodium carbonate anhydrous	38	g
20 Sorbitol	160	g
Antifoam M	5.8	g

The premix was passed through a 0.5 mm sieve.

25 Final mixing (for 400 tablets) was performed in the same Kenwood mixer where the following ingredients were dry mixed:

Effervescent granules from above	910	g
Premix from above	204	g
30 Sodium steryl fumarate (passing sieve 0.5 mm)	7	g

Enteric coated pellets from above 128 g

Compression to tablets was done on a tableting machine equipped with punches giving 25 mm diameter flat tablets.

5

Tablet weight was 3120 mg. The compressed tablets had an average height of 4.6 mm (n=4) and an average hardness of 67 N (n= 10). The effervescence time of the tablets was measured by putting the tablet in a basket of metal wiring and then immersing the basket in 150 ml of water (20 degrees Celsius). The effervescence time was considered finished when there was no material left in the immersed basket. For this tablet composition the time was 55 seconds.

10

The pH of the obtained dispersion when testing the tablet in 150 ml purified water was 5.0. Gastric juice resistance (determined as % of the dose omeprazole remaining after exposure for 0.1 M HCL during 2 hours) was 94%.

15

Example 5

Effervescent tablets containing 60 mg omeprazole.

20 Manufacturing of pellets.

Core material

Suspension for layering

Magnesium omeprazole	5.5 kg
25 Hydroxypropyl methylcellulose	0.8 kg
Water purified	15.7 kg

Seeds for layering

Non-pareil cores	11.0 kg
------------------	---------

30

The active substance was suspended in a solution prepared of the hydroxypropyl methylcellulose in the water, and thereafter homogenized in a ball mill.

The suspension was sprayed onto the seeds in a Wurster equipped fluidized bed apparatus.

5 Separating layer

	Core material (acc. to above)	16 kg
	Hydroxypropyl cellulose	1.6 kg
	Talc	2.7 kg
	Magnesium Stearate	0.2 kg
10	Water purified	32 kg

The talc and magnesium stearate were suspended in a solution prepared by dissolving the hydroxypropyl cellulose in the water. The suspension was sprayed onto the core material in the same equipment as above.

15

Enteric coating layer

	Prepared pellets (acc. to above)	20 kg
	Methacrylic acid copolymer (30% dispersion)	33 kg
20	Triethyl citrate	3 kg
	Mono- and diglycerides (NF)	0.5 kg
	Polysorbate 80	0.05kg
	Water purified	20.5 kg

25 The methacrylic acid copolymer dispersion was mixed with 1.0 kg of water and the triethylcitrate during agitation. (= Dispersion A.)

The polysorbate 80 was mixed with 19.5 kg of water, whereafter the mono- and diglycerides was added and this mixture was heated to above 70°C for 10 minutes and the
30 cooled during agitation to room temperature. (= Emulsion B.)

The emulsion B was added to suspension A and mixed to homogeneity.

The suspension (during agitation with a magnetic stirrer) was sprayed onto the core material
5 in a Wurster equipped fluidized bed apparatus.

Directly after the enteric coating dispersion was applied, the pellets in the fluidized bed were
sprayed with a hydroxypropyl methylcellulose solution containing magnesium stearate
dispersed therein to accomplish an overcoating layer.

10 The composition of the dispersion was;

Water purified	8 kg
Hydroxypropyl methylcellulose	0.4 kg
Magnesium stearate	0.01kg

15

The obtained (overcoated) enteric coated pellets were mixed with powders and effervescent
granules and thereafter compressed to effervescent tablets.

20 Effervescent granules;

Citric acid anhydrous	11.4 kg
Sodium bicarbonate	8.4 kg
Polyvinylpyrrolidone K-25 (PVP K-25)	0.3 kg
EtOH 99%(w/v)	0.8 kg
25 water purified	0.3 kg

The PVP K-25 was dissolved in the ethanol + water to give the granulating solution. This
solution was used to granulate the citric acid sodium bicarbonate mixture. The wet mass
was dried at 55°C and after cooling to room temperature the granulate was milled to pass
30 sieve 1.1 mm.

A pre-mix (for 400 tablets) was prepared by dry mixing in a Kenwood mixer the following:

	Sodium carbonate anhydrous	38 g
5	Sorbitol	160 g
	Antifoam M	5.8 g

The premix was passed through a 0.5 mm sieve.

- 10 Final mixing (for 400 tablets) was performed in the same Kenwood mixer where the following ingredients were dry mixed:

	Effervescent granules from above	910 g
	Premix from above	204 g
15	Sodium steryl fumarate (passing sieve 0.5 mm)	7 g
	Enteric coated pellets from above	191 g

Compression to tablets was done on a tableting machine equipped with punches giving 25 mm diameter flat tablets.

20

Tablet weight was 3230 mg. The compressed tablets had an average height of 4.9 mm (n=4) and an average hardness of 51 N (n= 10). The effervescence time of the tablets was measured by putting the tablet in a basket of metal wiring and then immersing the basket in 150 ml of water (20 degrees Celsius). The effervescence time was considered finished when
25 there was no material left in the immersed basket. For this tablet composition the time was 58 seconds.

The pH of the obtained dispersion when testing a tablet in 150 ml purified water was 5.0. Gastric juice resistance (determined as % of the dose omeprazole remaining after exposure
30 for 0.1 M HCl during 2 hours) was 94%...

Example 6

Effervescent tablets containing 20 mg S-omeprazole magnesium salt.

5 Manufacturing of pellets.

Core materialSuspension for layering

	S-omeprazole magnesium	300	g
10	micronized.		
	Hydroxypropyl methylcellulose	75	g
	Water purified	1425	g

Seeds for layering

15	Non-pareil cores	300	g
----	------------------	-----	---

The active substance was suspended in a solution prepared of the hydroxypropyl methylcellulose in the water. The suspension was sprayed onto the seeds in a Wurster equipped fluidized bed apparatus.

20

Separating layer

	Core material (acc. to above)	294	g
	Hydroxypropyl cellulose	29	g
	Talc	50	g
25	Magnesium Stearate	4	g
	Water purified	588	g

The talc and magnesium stearate were suspended in a solution prepared by dissolving the hydroxypropyl cellulose in the water. The suspension was sprayed onto the core material in
30 the same equipment as above.

Enteric coating layer

Prepared pellets (acc. to above) 300 g

5 Methacrylic acid copolymer (30% dispersion) 400 g

Triethyl citrate 36 g

Mono- and diglycerides (NF) 6 g

Polysorbate 80 0.6 g

Water purified 235 g

10

The methacrylic acid copolymer dispersion was mixed with the triethylcitrate during agitation. (= Dispersion A.)

15 The polysorbate 80 and the mono-and diglycerides were mixed with the water, whereafter this mixture was heated to above 70°C for 10 minutes and emulsified in a mixer. Then it was cooled during agitation to room temperature. (= Emulsion B.)

The emulsion B was added to Dispersion A and mixed to homogeneity.

20 The obtained dispersion was sprayed onto the core material in a Wurster equipped fluidized bed apparatus.

Directly after the enteric coating dispersion was applied, the pellets in the fluidized bed were sprayed with a hydroxypropyl methylcellulose solution containing magnesium stearate
25 dispersed therein to accomplish an overcoating layer.

The composition of this dispersion was;

Water purified 120 g
Hydroxypropyl methylcellulose 6 g
30 Magnesium stearate 0.3 g

Preparation of effervescent tablets.

The obtained (overcoated) enteric coated pellets were mixed with powders and effervescent granules and thereafter compressed to effervescent tablets.

5

Effervescent granules;

Citric acid anhydrous 11.4 kg

Sodium bicarbonate 8.4 kg

Polyvinylpyrrolidone K-25 (PVP K-25) 0.3 kg

10 EtOH 99%(w/v) 0.8 kg

water purified 0.3 kg

15

The PVP K-25 was dissolved in the ethanol + water to give the granulating solution. This solution was used to granulate the citric acid sodium bicarbonate mixture. The wet mass was dried at 55°C and after cooling to room temperature the granulate was milled to pass sieve 1.1 mm.

A pre-mix (for 50 tablets) was prepared by dry mixing in a mixer the following;

20

Sodium carbonate anhydrous 4.8 g

Sorbitol 20 g

Antifoam M 0.7 g

25

The premix was passed through a 0.5 mm sieve.

Final mixing (for 50 tablets) was performed in the same mixer where the following ingredients were dry mixed:

30

Effervescent granules from above 114 g

Premix from above 25.5 g

Sodium steryl fumarate (passing sieve 0.5 mm)	0.9 g
Enteric coated pellets from above	4.7 g

Compression to tablets was done on a tableting machine equipped with punches giving 25
5 mm diameter flat tablets.

Tablet weight was 2890 mg. The compressed tablets had an average height of 4.2 mm
(n=4) and an average hardness of 100 N (n= 5). The effervescence time of the tablets were
measured by putting the tablet in a basket of metal wiring and then immersing the basket in
10 150 ml of water (20 degrees Celsius). The effervescence time was considered finished when
there was no material left in the immersed basket. For this tablet composition the time was
55 seconds.

The pH of the obtained dispersion when testing in a tablet in 150 ml purified water was 5.0.
15

Gastric juice resistance (determined as % of the dose S-omeprazole remaining after
exposure for 0.1 M HCl during 2 hours) was 94%.

The enteric coating layered pellets comprising a proton pump inhibitor may also be prepared
20 as described in the following examples.

Example 7

Preparation of enteric coating layered pellets by extrusion/spheronization.

25

Core material

Magnesium omeprazole	600 g
Mannitol	1000 g
Microcrystalline cellulose	300 g
30 Hydroxypropyl cellulose	100 g

Sodium lauryl sulphate	6 g
Water purified	802 g

Separating layer

5 Core material (acc. to above)	400 g
Hydroxypropyl methylcellulose	48 g
Water purified	960 g

Enteric coating layer

10 Pellets covered with separating layer (acc. to above)	200 g
Methacrylic acid copolymer	100 g
Triethyl citrate	30 g
Mono- and diglycerides (NF)	5 g
Polysorbate 80	0.5 g
15 Water purified	309 g

Sodium lauryl sulphate is dissolved in purified water to form the granulation liquid.

Magnesium omeprazole, mannitol, microcrystalline cellulose and hydroxypropyl cellulose are dry-mixed. The granulation liquid is added to the powder mixture and the mass is wet-
 20 mixed.

The wet mass is forced through an extruder equipped with screens of size 0.5 mm. The extrudate is spheronized on a friction plate in a spheronizing apparatus. The core material is dried in a fluid bed dryer and classified. The prepared core material is covered by a
 25 separating layer in a fluid bed apparatus with a hydroxypropyl methylcellulose/water solution.

The enteric coating layer is applied to the pellets covered with separating layer from an aqueous dispersion of methacrylic acid copolymer plasticized with triethyl citrate to which a
 30 mono- and diglycerides/polysorbate dispersion has been added. The pellets are dried in a fluid bed apparatus.

Example 8

Preparation of enteric coating layered pellets by powder layering of sugar sphere seeds.

5

Core material

	Magnesium omeprazole	1 500 g
	Sugar sphere seeds	1 500 g
	Hydroxypropyl methylcellulose	420 g
10	Aerosil®	8 g
	Water purified	4 230 g

Separating layer

	Core material (acc. to above)	500 g
15	Hydroxypropyl cellulose	40 g
	Talc	67 g
	Magnesium stearate	6 g
	Water purified	800 g

20 Enteric coating layer

	Pellets covered with separating layer (acc. to above)	500 g
	Methacrylic acid copolymer	200 g
	Triethyl citrate	60 g
	Water purified	392 g

25

Magnesium omeprazole, part of the hydroxypropyl methylcellulose and Aerosil® are dry-mixed forming a powder. Sugar sphere seeds (0.25-0.40 mm) are layered with the powder in a centrifugal fluidized coating granulator while spraying a hydroxypropyl methylcellulose solution (6 %, w/w).

30

The prepared core material is dried and covered by a separating layer in a centrifugal fluidized coating-granulator. A fluid bed apparatus is used for enteric coating layering.

Example 9

- 5 Preparation of enteric coating layered pellets with silicon dioxide seeds.

Core material

	Magnesium omeprazole	8.0 kg
10	Silicon dioxide	8.0 kg
	Hydroxypropyl methylcellulose	1.4 kg
	Sodium lauryl sulphate	0.1 kg
	Water purified	28.0 kg

15 Separating layer

	Core material (acc. to above)	10.0 kg
	Hydroxypropyl methylcellulose	0.8 kg
	Water purified	10.0 kg

20 Enteric coating layer

	Pellets covered with separating layer (acc. to above)	300 g
	Methacrylic acid copolymer	124 g
	Polyethylene glycol 400	25 g
	Mono- and diglycerides (NF)	3 g
25	Polysorbate 80	1 g
	Water purified	463 g

- Suspension layering is performed in a fluid bed apparatus. Magnesium omeprazole is sprayed onto the silicon dioxide seeds from a water suspension containing the dissolved
- 30 binder and a surface active ingredient.

The prepared core material is covered with a separating layer in a fluid bed apparatus with a hydroxypropyl methylcellulose solution. The enteric coating layer consisting of methacrylic acid copolymer, mono- and diglycerides, polyethylene glycol 400 and polysorbate is sprayed onto the pellets covered with separating layer in a fluid bed apparatus.

5

Example 10

Preparation of enteric coating layered pellets.

10 Enteric coating layer

Pellets covered with separating layer

(manufacturing and composition

as in example 2)

500 g

Methacrylic acid copolymer

250 g

15 Polyethylene glycol 6000

75 g

Mono- and diglycerides (NF)

12.5 g

Polysorbate 80

1.2 g

Water purified

490 g

20 Example 11

Preparation of enteric coating layered pellets.

Enteric coating

25 Pellets covered with separating layer

500 g

(manufacturing and composition as in example 1)

Hydroxypropyl methylcellulose phthalate

250 g

Cetanol

50 g

Ethanol (95%)

1000 g

30 Acetone

2500 g

Example 12

Preparation of enteric coating layered pellets.

5	<u>Core material</u>	
	Omeprazole	225 g
	Mannitol	1425 g
	Hydroxypropyl cellulose	60 g
	Microcrystalline cellulose	40 g
10	Lactose anhydrous	80 g
	Sodium lauryl sulphate	5 g
	Disodium hydrogen phosphate dihydrate	8 g
	Water purified	350 g
15	<u>Separating layer</u>	
	Core material (acc. to above)	300 g
	Hydroxypropyl cellulose	30 g
	Talc	51 g
	Magnesium stearate	4 g
20	<u>Enteric coating layer</u>	
	Pellets covered with separating layer (acc. to above)	300 g
	Methacrylic acid copolymer	140 g
	Triethyl citrate	42 g
25	Mono- and diglycerides (NF)	7 g
	Polysorbate 80	0.7 g

The dry ingredients for producing the core material are well mixed in a mixer. Addition of granulation liquid is made and the mixture is kneaded and granulated to a proper consistency. The wet mass is pressed through an extruder screen and the granules are converted into a spherical form in a spheronizer. The core material is dried in a fluid bed


apparatus and classified into a suitable particle size range, e.g. 0.5 - 1.0 mm. The prepared core material is covered with a separating layer and is enteric coating layered as described in previous examples.

5 Preparation of active substance.

Magnesium omeprazole used in some of the examples is produced according to the process described in WO95/01977, the single enantiomers of omeprazole salts are prepared as described in WO94/27988 and omeprazole is produced according to the process disclosed
10 in EP-A1 0005129. These documents are hereby incorporated in a whole by reference.


Claims

1. A tableted multiple unit effervescent dosage form comprising effervescent tablet constituents and enteric coating layered units of a core material comprising an acid susceptible proton pump inhibitor in the form of the racemate, an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, optionally admixed with alkaline reacting compounds, the core material is coating layered with one or more coating layers, at least one of which is an enteric coating layer, characterized in that the enteric coating layer(s) has mechanical properties such that the compression of the enteric coating layered units with the effervescent tablet constituents into the multiple unit tableted dosage form does not significantly affect the acid resistance of the enteric coating layered units.
2. A tableted effervescent dosage form according to claim 1, wherein the proton pump inhibitor is a compound of the general formula I in the form of the racemate, an alkaline salt or one of its single enantiomers or an alkaline salt thereof




wherein

Het₁ is




or




Het₂ is

46



X =



wherein

5

N in the benzimidazole moiety means that one of the carbon atoms substituted by R_6 - R_9 optionally may be exchanged for a nitrogen atom without any substituents;

R_1 , R_2 and R_3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

10

R_4 and R_5 are the same or different and selected from hydrogen, alkyl and aralkyl;

R'_6 is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

15


R_6 - R_9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxy carbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R_6 - R_9 form ring structures which may be further substituted;

R_{10} is hydrogen or forms an alkylene chain together with R_3 and



20


R₁₁ and R₁₂ are the same or different and selected from hydrogen, halogen or alkyl and alkyl groups, alkoxy groups and moieties thereof may be branched and straight C₁-C₉-chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

- 5 3. A tableted effervescent dosage form according to claim 1, wherein the proton pump inhibitor is one of the following compounds





10









5





10



49



5



10

4. A tableted effervescent dosage form according to claim 1, wherein the proton pump inhibitor is omeprazole, an alkaline salt thereof, or S-omeprazole or an alkaline salt thereof.
5. A tableted effervescent dosage form according to claim 1, wherein the acid resistance of the enteric coating layered units is in coherence with the requirements on enteric coated articles defined in the United States Pharmacopeia USP.
6. A tableted effervescent dosage form according to claim 1, wherein the acid resistance of the enteric coating layered units does not decrease more than 10 % during the compression of the enteric coating layered units into the tableted multiple unit effervescent dosage form.
7. A tableted effervescent dosage form according to claim 1, wherein the enteric coating layer of the individual units comprises a plasticized enteric coating material.
8. A tableted effervescent dosage form according to claim 7, wherein the enteric coating layer of the individual units have been prepared from water-based polymer systems.
9. A tableted effervescent dosage form according to claim 1, wherein the enteric coating layer of the individual units has a thickness of at least 10 μ m.
10. A tableted effervescent dosage form according to claim 1, wherein each individual of the enteric coating layered units are further coated with an over-coat comprising filmforming agents and optionally pharmaceutically acceptable excipients.
11. A tableted effervescent dosage form according to claim 1, wherein the effervescent tablet constituents are a carbon dioxide source and a solid acidic compound and optionally other tablet excipients.

12. A tableted effervescent dosage form according to claim 1, wherein the effervescent tablet constituents are sodium carbonate and bicarbonate, citric acid and optionally other tablet excipients.

5 13. A tableted effervescent dosage form according to claim 1, wherein a separating layer is optionally applied in between the core material and the enteric coating layer, characterized in that the separating layer(s) comprises polymeric, filmforming compounds or tablet excipients which are soluble, or insoluble but disintegrating in water, and optionally pH-buffering, alkaline compounds.

10

14. A tableted effervescent dosage form according to claim 1, wherein the proton pump inhibitor is optionally mixed with excipients and alkaline reacting material and spray layered onto inert seeds.

15 15. A tableted effervescent dosage form according to claim 14, wherein the inert seeds have a size of 0.1 - 2 mm.

16. A tableted effervescent dosage form according to claim 14, wherein the inert seeds are soluble sugar seeds.

20

17. A tableted effervescent dosage form according to claim 1, wherein the proton pump inhibitor is mixed with excipients and optionally alkaline reacting material and extruded into homogenous cores.

25 18. A process for the manufacture of a tableted multiple unit effervescent dosage form comprising mixing effervescent tablet constituents and enteric coating layered units of a core material comprising an acid susceptible proton pump inhibitor optionally mixed with alkaline reacting compounds, and said core material is optionally covered with one or more separating layer(s) and further covered with one or more enteric coating layer(s), whereafter
30 the enteric coating layered units are compressed together with the effervescent tablet constituents into a tablet, whereby the enteric coating layer(s) has mechanical properties

such that the compression of the enteric coated units with the effervescent tablet constituents into the tableted dosage form does not significantly affect the acid resistance of the enteric coating layered units.

5 19. A process according to claim 18, wherein the enteric coating layered units are further coated with an over-coat before compression of the units together with the effervescent tablet constituents into the tableted dosage form.

20. A method for inhibiting gastric acid secretion in mammals and man by administering to
10 a host in need thereof a therapeutically effective dose of a tableted multiple unit effervescent dosage form according to any of claims 1 to 17.

21. A method for the treatment of gastrointestinal inflammatory diseases in mammals and man by administering to a host in need thereof a therapeutically effective dose of a tableted
15 multiple unit effervescent dosage form according to any of claims 1 to 17.

22. Use of a tableted effervescent dosage form according to any of claims 1 - 17 for the manufacture of a medicament for inhibiting gastric acid secretion.

20 23. Use of a tableted effervescent dosage form according to any of claims 1 - 17 for the manufacture of a medicament for treating gastrointestinal inflammatory diseases.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/01738

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/46, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, WPI, WPIL, CLAIMS, CAPLUS, USFULLTEXT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4289751 A (J.J. WINDHEUSER), 15 Sept 1981 (15.09.81), column 2, line 9 - line 43; column 3, line 19 - line 55, claims --	1-23
A	WO 9421239 A1 (CIMA LABS, INC.), 29 Sept 1994 (29.09.94), page 6, line 20 - page 7, line 16, claims --	1-23
A	EP 0233853 A1 (LABORATORIES SMITH KLINE & FRENCH), 26 August 1987 (26.08.87) -- -----	1-23

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

9 April 1997

Date of mailing of the international search report

22 -04- 1997

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/01738

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20-21
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Claims 20-21 are directed to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/SE 96/01738

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	4289751	A	15/09/81	NONE	
WO	9421239	A1	29/09/94	AU 6447294 A EP 0752852 A US 5503846 A	11/10/94 15/01/97 02/04/96
EP	0233853	A1	26/08/87	SE 0233853 T3 AU 599071 B AU 6789987 A BG 50924 A CA 1299583 A CN 1032841 B EG 18194 A FI 90941 C FR 2593065 A,B IE 59652 B JP 8175976 A JP 62215536 A KR 9502883 B NO 173972 C OA 8464 A SU 1605913 A US 4824664 A	12/07/90 23/07/87 15/12/92 28/04/92 25/09/96 30/11/94 25/04/94 24/07/87 09/03/94 09/07/96 22/09/87 28/03/95 02/03/94 29/07/88 07/11/90 25/04/89